Aktienanalyse zu Perrigo Company PLC (PRGO)PRGOPerrigo Company PLC

Perrigo Company plc is a pure-play self-care company. The Company provides health and wellness solutions. Its segments include Self Care, Specialty Care, and Infant Formula. Self Care comprises Upper Respiratory, Digestive Health, Pain & Sleep and Healthy Lifestyle product categories globally. Specialty Care comprises our Women's Health and Skin Health product categories globally. Infant Formula comprises the Infant Formula product category, which includes nutritional products designed to meet the dietary needs of infants. It provides a store-branded private label provider of self-care products in many categories, including upper respiratory, healthy lifestyle and women's health, along with brands including Opill and Mederma. Its Europe portfolio consists primarily of brands, including Compeed, ellaOne, Solpadeine, Jungle Formula, and ACO. Its upper respiratory products include Nasonex 24HR Energy, Mucus DM, All Day Allergy, Nighttime Cold & Flu, and Allergy Relief. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Perrigo is currently trading at $14.48, which is slightly above the analyst target price of $14.50, indicating some market optimism. However, the company has reported a significant decline in core sales by 3.1% year-over-year and a drop in organic sales by 3.5%, which raises concerns about its financial health. Additionally, the abrupt departure of the CEO adds uncertainty to the company's future strategies. Given these factors, it may be prudent to hold off on buying until there is more clarity on the company's direction and performance.

18 analysts cover PRGO: 6 rate it Buy, 11 Hold and 1 Sell. The average price target is 20.33.